

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**INSIDE INFORMATION
POTENTIAL DISPOSAL OF TIANMAI BIOTECHNOLOGY**

This announcement is made by China Resources Pharmaceutical Group Limited (the “**Company**” together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company hereby announces that China Resources Pharmaceutical Investment Company Limited (華潤醫藥投資有限公司) (“**CR Pharmaceutical Investment**”), a wholly-owned subsidiary of the Company, has initiated the potential disposal (the “**Potential Disposal**”) of approximately 17.87% equity interests held by CR Pharmaceutical Investment and its subsidiary in Hefei Tianmai Biotechnology Development Co., Ltd. (合肥天麥生物科技發展有限公司) (“**Tianmai Biotechnology**”) through a public tender process on the Shanghai United Assets and Equity Exchange (上海聯合產權交易所) at a minimum listing price of approximately RMB1.42 billion. As of the date of this announcement, CR Pharmaceutical Investment and its subsidiary held less than 30% equity interests in Tianmai Biotechnology.

Should any intended transferee be identified, CR Pharmaceutical Investment and its subsidiary will enter into relevant transaction agreements with such transferee in respect of the Potential Disposal. If no intended transferee is identified, the public tender process shall automatically lapse and terminate. The Company will comply with the applicable requirements under Chapter 14 of the Listing Rules upon the execution of the relevant transaction agreements as and if required.

As of the date of this announcement, no intended transferee has been identified and no definitive transaction agreements have been entered into by the Group for the Potential Disposal. The Potential Disposal is subject to various factors, including successful completion of the public tender process and execution of relevant agreements and conditions as set forth therein. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 9 February 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.